**Author details**

Ruchika Meel Division of Cardiology, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

\*Address all correspondence to: ruchikameel@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**73**

*Role of Medical Therapy in Chronic Mitral Regurgitation*

system and the left ventricular adaptation to mitral regurgitation. Journal of the American College of

[10] Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: Implications for management. Circulation. 2008;**118**:2298-2303

[11] Baumgartner H, Falk V, Bax JJ, De Bonis M, et al. ESC/EACTS guidelines for the management of valvular heart disease. European Heart Journal.

[12] Gaasch WH, Otto CM. Vaosdilator

Regurgitation. In: UpToDate, Post TW, editors. Waltham, MA: UpToDate; 2018

[13] Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. The Journal of Clinical Investigation.

[14] Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. Journal of the American College of Cardiology.

[15] Dujardin KS, Enriquez-Sarano M, Bailey KR, et al. Effect of losartan on degree of mitral regurgitation quantified by echocardiography. The American Journal of Cardiology.

[16] Rosario LB, Stevenson LW, Solomon SD, et al. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: Importance of reduction in the regurgitant orifice size. Journal of the American College of Cardiology.

Cardiology. 2002;**39**:1380

2017;**38**:2739-2791

1994;**93**:2639-2648

1996;**28**:1083

2001;**87**:570

1998;**32**:1819

Therapy in Chronic Mitral

*DOI: http://dx.doi.org/10.5772/intechopen.89027*

[1] Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure focus on cardiac hypertrophy, inflammation,

angiogenesis, and apoptosis. Journal of the American College of Cardiology.

[2] Cohn J, Ferrari R, Sharpe N. Cardiac remodeling—Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Journal of the American College of Cardiology. 2000;**35**:569-582

[3] Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. Vol. 9. Philadelphia: Elsevier Saunders;

[4] Casaclang-Verzosa G, Gersh B, Tsang T. Structural and functional remodeling of the left atrium. Clinical and therapeutic implications for atrial fibrillation. Journal of the American College of Cardiology. 2008;**51**:1-11

[5] Carabello BA. The current therapy for mitral regurgitation. Journal of the American College of Cardiology.

Pathophysiology of Chronic Mitral Regurgitation. In: UpToDate, Post TW, editors. Waltham, MA: UpToDate; 2019

[7] Meel R et al. The changing spectrum of rheumatic mitral regurgitation in Soweto, South Africa. Cardiovascular Journal of Africa. 2017;**28**:215-220

[8] Topilsky Y, Michelena H, Bichara V, et al. Mitral valve prolapse with midlate systolic mitral regurgitation: Pitfalls of evaluation and clinical outcome compared with holosystolic regurgitation. Circulation. 2012;**125**:1643

[9] Gaasch WH, Aurigemma GP. Inhibition of the renin-angiotensin

**References**

2006;**48**:A56-A66

2012

2008;**52**:319-326

[6] Gaasch WH, Otto CM.

*Role of Medical Therapy in Chronic Mitral Regurgitation DOI: http://dx.doi.org/10.5772/intechopen.89027*
